Pilar Blancafort
Overview
Explore the profile of Pilar Blancafort including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1708
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Woodward E, Wang E, Wallis C, Sharma R, Tie A, Murthy N, et al.
Methods Mol Biol
. 2024 Jul;
2842:267-287.
PMID: 39012601
Genome editing tools, particularly the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) systems (e.g., CRISPR/Cas9), and their repurposing into epigenetic editing platforms, offer enormous potential as safe and customizable therapies...
2.
Waryah C, Alves E, Mazzieri R, Dolcetti R, Thompson E, Redfern A, et al.
Cancers (Basel)
. 2023 Jun;
15(12).
PMID: 37370762
Cellular plasticity in cancer enables adaptation to selective pressures and stress imposed by the tumor microenvironment. This plasticity facilitates the remodeling of cancer cell phenotype and function (such as tumor...
3.
Waryah C, Cursons J, Foroutan M, Pflueger C, Wang E, Molania R, et al.
Adv Sci (Weinh)
. 2023 May;
10(22):e2301802.
PMID: 37217832
Epithelial-mesenchymal transition (EMT) is a reversible transcriptional program invoked by cancer cells to drive cancer progression. Transcription factor ZEB1 is a master regulator of EMT, driving disease recurrence in poor-outcome...
4.
Sgro A, Cursons J, Waryah C, Woodward E, Foroutan M, Lyu R, et al.
Clin Epigenetics
. 2023 Apr;
15(1):73.
PMID: 37120619
Background: Epigenetic silencing of tumor suppressor genes (TSGs) is a key feature of oncogenesis in hepatocellular carcinoma (HCC). Liver-targeted delivery of CRISPR-activation (CRISPRa) systems makes it possible to exploit chromatin...
5.
Kim M, Singh M, Lee B, Hibbs M, Richardson K, Ellies L, et al.
Oncogenesis
. 2022 Oct;
11(1):60.
PMID: 36207293
The MYC proto-oncogene (MYC) is one of the most frequently overexpressed genes in breast cancer that drives cancer stem cell-like traits, resulting in aggressive disease progression and poor prognosis. In...
6.
de Mendoza A, Nguyen T, Ford E, Poppe D, Buckberry S, Pflueger J, et al.
Genome Biol
. 2022 Jul;
23(1):163.
PMID: 35883107
Background: Cytosine DNA methylation is widely described as a transcriptional repressive mark with the capacity to silence promoters. Epigenome engineering techniques enable direct testing of the effect of induced DNA...
7.
Design and Characterization of a Cell-Penetrating Peptide Derived from the SOX2 Transcription Factor
Gandhi N, Wang E, Sorolla A, Kan Y, Malik A, Batra J, et al.
Int J Mol Sci
. 2021 Sep;
22(17).
PMID: 34502261
SOX2 is an oncogenic transcription factor overexpressed in nearly half of the basal-like triple-negative breast cancers associated with very poor outcomes. Targeting and inhibiting SOX2 is clinically relevant as high...
8.
Alves E, McLeish E, Blancafort P, Coudert J, Gaudieri S
Front Immunol
. 2021 Aug;
12:712722.
PMID: 34456921
The activating immune receptor natural killer group member D (NKG2D) and its cognate ligands represent a fundamental surveillance system of cellular distress, damage or transformation. Signaling through the NKG2D receptor-ligand...
9.
Alves E, Taifour S, Dolcetti R, Chee J, Nowak A, Gaudieri S, et al.
Mol Ther Methods Clin Dev
. 2021 Jun;
21:592-606.
PMID: 34095343
Precise clustered regularly interspaced short palindromic repeats (CRISPR)-mediated genetic and epigenetic manipulation of the immune response has become a promising immunotherapeutic approach toward combating tumorigenesis and tumor progression. CRISPR-based immunologic...
10.
Golden E, Rashwan R, Woodward E, Sgro A, Wang E, Sorolla A, et al.
Nat Commun
. 2021 Mar;
12(1):1920.
PMID: 33772001
Adipogenesis associated Mth938 domain containing (AAMDC) represents an uncharacterized oncogene amplified in aggressive estrogen receptor-positive breast cancers. We uncover that AAMDC regulates the expression of several metabolic enzymes involved in...